ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

Rhea-AI Summary

ASLAN Pharmaceuticals (NASDAQ: ASLN) announced that data from the Phase 1b dose escalation study of ASLAN004 for atopic dermatitis will be presented at the 2022 Winter Clinical Dermatology Conference in Koloa, Hawaii, from January 14-19, 2022. This study involved 25 patients and focuses on the safety and efficacy of ASLAN004, a monoclonal antibody targeting the IL-13 receptor. The data will also be showcased at the MauiDerm Conference from January 24-28, 2022. ASLAN004 is being developed as a first-in-class treatment for moderate-to-severe atopic dermatitis.

- Data from Phase 1b dose escalation cohorts to be presented during the 2022 Winter Clinical Dermatology Conference, held in-person from 14-19 January, 2022, in Koloa, Hawaii

- Data will also be presented as an encore presentation at the MauiDerm Conference, held in-person and virtually from 24-28 January, 2022, in Maui, Hawaii

MENLO PARK, Calif. and SINGAPORE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that the results from the dose escalation portion of the completed Phase 1b Proof-of-Concept study of ASLAN004 in atopic dermatitis (AD) have been accepted for poster presentation at the 2022 Winter Clinical Dermatology Conference, to be held in Koloa, Hawaii, January 14-19, 2022. The poster will provide further details on the safety, tolerability and efficacy of ASLAN004 in the dose escalation portion of the multiple ascending dose study in 25 patients. The Company also announced these data will be presented in an encore presentation at the MauiDerm Conference, held in Maui, Hawaii, January 24-28.

ASLAN004 is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for patients. In September 2021, ASLAN announced positive results from the Phase 1b Proof-of-Concept study and supported its potential as a differentiated, novel treatment for AD.

2022 Winter Clinical Dermatology Conference Poster details

Title: Interim analysis results from a Proof-of-Concept study for ASLAN004 in adult moderate-to-severe atopic dermatitis: a double blind, randomized, placebo-controlled study

Presenter: Dr Karen Veverka, VP Medical, ASLAN Pharmaceuticals

Location: Poster Gallery, Grand Promenade of the Grand Hyatt Kauai

Viewing dates: 15-18 January 2022

The poster will be available to view online in the Investor Relations section of ASLAN’s website following presentation: https://ir.aslanpharma.com/. The poster results will also be presented in-person as an encore presentation at the MauiDerm Conference from 24-28 January 2022.

More information on the presentations available during the events can be found here:
https://fallclinical.health/wc22-agenda
https://mauiderm.com/maui-derm-dermatologists-2020-program-2-2-2-3/

Media and IR contacts

Emma Thompson  Spurwing Communications  Tel: +65 6206 7350  Email: ASLAN@spurwingcomms.com

Ashley R. Robinson  LifeSci Advisors, LLC  Tel: +1 (617) 430-7577   Email: arr@lifesciadvisors.com

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

 

FAQ

What are the dates of the 2022 Winter Clinical Dermatology Conference where ASLN will present data?

The conference will be held from January 14-19, 2022.

What is ASLAN004 and its significance for atopic dermatitis?

ASLAN004 is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, developed for treating atopic dermatitis.

Where can I find the poster presentation details for ASLN at the MauiDerm Conference?

The details can be found in the Investor Relations section of ASLAN Pharmaceuticals' website after the presentation.

What kind of study was conducted for ASLAN004?

The study was a Phase 1b Proof-of-Concept clinical trial focusing on safety and efficacy in patients with moderate-to-severe atopic dermatitis.

Who will present the ASLN data at the 2022 Winter Clinical Dermatology Conference?

Dr. Karen Veverka, VP Medical at ASLAN Pharmaceuticals, will present the data.